Moors & Cabot Inc. increased its holdings in shares of Stryker Corporation (NYSE:SYK – Free Report) by 28.3% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 11,524 shares of the medical technology company’s stock after buying an additional 2,539 shares during the quarter. Moors & Cabot Inc.’s holdings in Stryker were worth $3,174,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors have also added to or reduced their stakes in the company. Bank of America Corp DE purchased a new stake in shares of Stryker during the second quarter valued at $1,404,284,000. Legal & General Group Plc acquired a new stake in Stryker during the 2nd quarter worth about $707,212,000. Jupiter Topco LLC acquired a new stake in Stryker during the 2nd quarter worth about $681,581,000. Corient Private Wealth LP purchased a new stake in Stryker during the 2nd quarter valued at about $323,035,000. Finally, Flossbach Von Storch SE purchased a new stake in Stryker during the 2nd quarter valued at about $464,506,000. Institutional investors and hedge funds own 77.09% of the company’s stock.
Stryker Price Performance
Shares of NYSE SYK traded down $3.34 during trading on Friday, hitting $309.05. The company had a trading volume of 3,251,740 shares, compared to its average volume of 3,235,306. The firm has a market capitalization of $117.65 billion, a price-to-earnings ratio of 32.91, a price-to-earnings-growth ratio of 2.14 and a beta of 0.78. The stock has a fifty day simple moving average of $292.30 and a two-hundred day simple moving average of $322.60. The company has a quick ratio of 1.30, a current ratio of 2.18 and a debt-to-equity ratio of 0.60. Stryker Corporation has a fifty-two week low of $267.00 and a fifty-two week high of $389.33.
Stryker (NYSE:SYK – Get Free Report) last issued its quarterly earnings results on Thursday, October 29th. The medical technology company reported $3.52 earnings per share for the quarter, missing analysts’ consensus estimates of $3.55 by ($0.03). Stryker had a net margin of 13.78% and a return on equity of 23.74%. The company had revenue of $6.52 billion during the quarter, compared to analysts’ expectations of $6.62 billion. During the same period in the prior year, the business posted $3.19 earnings per share. The company’s quarterly revenue was up 7.6% compared to the same quarter last year. On average, research analysts expect that Stryker Corporation will post 14.85 earnings per share for the current year.
Analysts Set New Price Targets
Several analysts have recently commented on the stock. Needham & Company LLC dropped their price objective on shares of Stryker from $418.00 to $359.00 and set a “buy” rating on the stock in a report on Friday, October 30th. Piper Sandler upped their price target on shares of Stryker from $325.00 to $350.00 and gave the company an “overweight” rating in a report on Monday, November 9th. Barclays reduced their price objective on Stryker from $375.00 to $365.00 and set an “overweight” rating for the company in a research note on Friday, October 30th. Raymond James Financial restated an “outperform” rating and issued a $323.00 target price (down from $370.00) on shares of Stryker in a research note on Friday, October 30th. Finally, Leerink Partners reduced their price target on Stryker from $403.00 to $353.00 and set an “outperform” rating for the company in a research report on Friday, October 9th. Twenty-one equities research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company. According to MarketBeat.com, Stryker has an average rating of “Moderate Buy” and an average price target of $342.19.
Read Our Latest Stock Report on SYK
Insider Activity
In other Stryker news, insider Dylan Crotty sold 441 shares of the stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $328.61, for a total value of $144,917.01. Following the completion of the sale, the insider owned 6,102 shares in the company, valued at approximately $2,005,178.22. This represents a 6.74% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Debra King sold 826 shares of the business’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total value of $277,783.80. Following the transaction, the insider owned 6,210 shares in the company, valued at approximately $2,088,423. This represents a 11.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 901,267 shares of company stock worth $297,123,701 over the last three months. Insiders own 4.60% of the company’s stock.
About Stryker
Stryker is a medical technology company that develops and sells products and services for healthcare providers. Its offerings include orthopedic implants and surgical equipment, neurotechnology and spine products, and medical and surgical equipment used in hospitals and other care settings. The company’s products also include patient-handling and emergency medical equipment, as well as instruments and technologies that support surgical procedures. Stryker serves healthcare customers in the United States and internationally.
Further Reading
- Five stocks we like better than Stryker
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK – Free Report).
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.
